Lipotype Inc. defeated Nextcea Inc.'s lawsuit claiming its lipid-analysis tests infringed a patented method for diagnosing certain medical conditions by using a specific biomarker after a federal court deemed the claims uninventive.
Nextcea’s US Patent No. 8,313,949 is invalid because it describes natural phenomena without providing any further action, according to a Feb. 6 order dismissing the suit. Under the two-part test laid out in the US Supreme Court’s 2014 decision in Alice Corp. v. CLS Bank, inventions that cover natural phenomenon are eligible for patent protection only if they include an inventive concept.
The patent’s claims are directed ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.